Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi
Information source: Centers for Disease Control and Prevention
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Malaria, Falciparum
Intervention: sulfadoxine-pyrimethamine (Drug); amodiaquine plus sulfadoxine-pyrimethamine (Drug); amodiaquine plus artesunate (Drug); chlorproguanil-dapsone plus artesunate (Drug); lumefantrine-artemether (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Centers for Disease Control and Prevention Official(s) and/or principal investigator(s): Rachel N Bronzan, MD, MPH, Principal Investigator, Affiliation: Centers for Disease Control and Prevention
Summary
Sulfadoxine-pyrimethamine (SP) is the current first-line treatment for uncomplicated malaria
in Malawi. The malaria parasite P. falciparum has developed resistance to this drug so that
the drug is much less effective than in previous years. This study was developed and
conducted in collaboration with the National Malaria Control Programme of Malawi to assess
the efficacy of four antimalarial drug combinations to provide evidence to assist the
Malawian Ministry of Health in identifying and implementing as policy the next first-line
antimalarial for uncomplicated malaria in Malawi. In an open, randomized trial in children
under five years of age, four drug combinations, all of which are licensed in Malawi, are
being assessed: amodiaquine plus sulfadoxine-pyrimethamine (AQ-SP), amodiaquine plus
artesunate (AQ-Art), chlorproguanil-dapsone plus artesunate (CD-Art) and
lumefantrine-artemether (LA). SP is also included as a fifth arm of the study for current
data on its efficacy. Data on side effects of the drugs will also be collected. The results
of this study will provide some of the information necessary to guide the Malawi National
Malaria Control Program in selecting its next first antimalarial treatment for uncomplicated
malaria. The study adheres to the World Health Organization's 2003 standardized protocol for
assessing antimalarial drug efficacy.
Clinical Details
Official title: An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: • Rate of Adequate Clinical and Parasitological Response at 14 days (WHO-defined measure of efficacy)
Secondary outcome: • Rate of Adequate clinical and parasitological response 28 days• Mean percent change in blood haemoglobin concentration between day 0 and day 28 • Incidence of adverse events during the period of observation • Rate of Early Treatment Failure (as defined by the WHO in their 2003 standardized protocol for assessing antimalarial drug efficacy) • Rate of Late Clinical Failure (as defined by the WHO) • Rate of Late Parasitologic Failure (as defined by the WHO) • Percent of patients with a decrease in haemoglobin concentration • Percent of patients with a decrease in haemoglobin concentration of ≥ 2g/dl • Prevalence of parasitemia on Day 2 • Prevalence of parasitemia on Day 3 • Gametocyte prevalence on Day 14 • Gametocyte prevalence on Day 28
Eligibility
Minimum age: 6 Months.
Maximum age: 59 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Children age 6 - 59 months
- Axillary temperature ≥ 37. 5 °C
- Monoinfection with P. falciparum
- Parasitaemia between 2000 - 200000 parasites/µl
- Haemoglobin concentration (finger-prick blood sample by HemoCue) > 7g/dl
- Consent by the patient's adult guardian
- Residence in the locality and willingness to attend for scheduled visits
Exclusion Criteria:
- altered consciousness
- convulsions
- prostration (inability to sit/stand/suck/drink)
- respiratory distress or breathlessness
- jaundice
- abnormal breathing
- haemoglobinuria
- circulatory collapse
- persistent vomiting (cannot keep down liquids)
- evidence of a diagnosis other than malaria on physical examination
- presence of mixed infection
- presence of severe malnutrition (as evidenced by symmetrical oedema involving at
least the feet, light hair color, or cachexia)
- contraindications to the antimalarial drugs used, especially history of allergy
- history of receiving a drug with antimalarial activity in the week prior to
enrollment
Locations and Contacts
Kawale Health Center, Lilongwe, Lilongwe District, Malawi
Machinga District Hospital, Liwonde, Machinga District, Malawi
Matiki Health Center, Dwangwa, Nkhotakota District, Malawi
Additional Information
Starting date: April 2005
Last updated: September 26, 2012
|